Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.
2.

Pharmacologic inhibitors of MKK1 and MKK2.

Ahn NG, Nahreini TS, Tolwinski NS, Resing KA.

Methods Enzymol. 2001;332:417-31. No abstract available.

PMID:
11305115
3.

Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry.

Lewis TS, Hunt JB, Aveline LD, Jonscher KR, Louie DF, Yeh JM, Nahreini TS, Resing KA, Ahn NG.

Mol Cell. 2000 Dec;6(6):1343-54.

4.

Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase.

Whalen AM, Galasinski SC, Shapiro PS, Nahreini TS, Ahn NG.

Mol Cell Biol. 1997 Apr;17(4):1947-58.

5.

Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects.

Harrison DA, Binari R, Nahreini TS, Gilman M, Perrimon N.

EMBO J. 1995 Jun 15;14(12):2857-65.

7.

Role for cyclic AMP in the postreceptor control of cytokine-stimulated stromal cell growth factor production.

Derigs HG, Burgess GS, Klingberg D, Nahreini TS, Mochizuki DY, Williams DE, Boswell HS.

Leukemia. 1990 Jul;4(7):471-9.

PMID:
2165202
8.

A RAS oncogene imparts growth factor independence to myeloid cells that abnormally regulate protein kinase C: a nonautocrine transformation pathway.

Boswell HS, Nahreini TS, Burgess GS, Srivastava A, Gabig TG, Inhorn L, Srour EF, Harrington MA.

Exp Hematol. 1990 Jun;18(5):452-60.

PMID:
2186924

Supplemental Content

Loading ...
Support Center